ArticleInfection and drug resistance2020
Treatment Failure in Urinary Tract Infections: A Warning Witness for Virulent Multi-Drug Resistant ESBL- Producing
Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 54 citations in OpenAlex.
- Antimicrobial resistance profile and molecular analysis of virulence among Escherichia coli isolated from pregnant women with asymptomatic bacteriuria in Gorgan, Iran.BMC pregnancy and childbirth · 2026Article
- Retrospective study on antibiotic resistance profiles of uropathogenicFrontiers in microbiology · 2026Article
- Bacteraemia due to E.coli in urinary tract infections in adults: a prospective epidemiological study following implementation of guidelines in a regional hospital.BMC infectious diseases · 2025Article
- Extended-Spectrum Beta-Lactamase Production and Carbapenem Resistance in Elderly Urinary Tract Infection Patients: A Multicenter Retrospective Study from Turkey.Antibiotics (Basel, Switzerland) · 2025Article
- Distribution of Fimbrial Genes and Their Association with Virulence and Levofloxacin Resistance/Extended-Spectrum Beta-Lactamase Production in UropathogenicAntibiotics (Basel, Switzerland) · 2025Article
- Rapid formulation of a genetically diverse phage cocktail targeting uropathogenic Escherichia coli infections using the UTI89 model.Scientific reports · 2025Article
- Effect of Inadequate Treatment in Adult Patients with Community-Acquired Acute Pyelonephritis Due to Enterobacterales Under Empirical Management with Cefazolin.Antibiotics (Basel, Switzerland) · 2025Article
- Multiplex PCR Amplification for the Detection of Biofilm and Extended-spectrum Beta-Lactamase Resistance Genes and Antibiotic Resistance Patterns in UropathogenicArchives of Razi Institute · 2025Article
- Detection of Integrons inInternational journal of microbiology · 2025Article
- Retrospective Analysis of Antibiotic Resistance Patterns of UropathogenicHealth science reports · 2025Article
- Canine urothelial cell model to study intracellular bacterial community development by uropathogenic Escherichia coli.PloS one · 2025Article
- Phylogenetic Diversity, Antibiotic Resistance, and Virulence ofAntibiotics (Basel, Switzerland) · 2024Article
- Antimicrobial resistance and ESBL production in uropathogenicJAC-antimicrobial resistance · 2024Review
- Horizontal transfer characterization of ColV plasmids in blaPoultry science · 2024Article
- Molecular typing and virulence characteristics of Escherichia coli strains isolated from hospital and community acquired urinary tract infections.Molecular biology reports · 2024Article
- It's uncomplicated: Prevention of urinary tract infections in an era of increasing antibiotic resistance.PLoS pathogens · 2024Article
- Detection of phylogrouping, adhesin, and extended spectrum β-lactamases genes in hospital acquired uropathogenic Escherichia coli isolates.Molecular biology reports · 2024Article
- Molecular Characterization of High and Low VirulentInfection and drug resistance · 2024Article
- Genotypic Characterization of UropathogenicAntibiotics (Basel, Switzerland) · 2023Article
- Biofilm Formation byMicroorganisms · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlobal increase in the prevalence of virulent extended-spectrum beta-lactamase (ESBL)-producing uropathogenic
methodsWe investigated the distribution of ESBL-producing UPEC in 78
resultsOf the UPECs, 34.6% were ESBL-positive and 96.3% of the ESBL-producers were MDR. Among the ESBL-producers, 100% harbored
conclusionThe alarming level of virulent MDR ESBL-producer
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.